Exploring Treatment Options for Breast Implant-Associated Anaplastic Large Cell Lymphoma скачать в хорошем качестве

Exploring Treatment Options for Breast Implant-Associated Anaplastic Large Cell Lymphoma

Lloyd B. Gayle, MD, director of plastic surgery, vice-chairman of surgery, Maimonides Medical Center, attending surgeon in plastics at the Hospital for Special Surgery, and an associate attending surgeon in the Division of Plastic Surgery at New York-Presbyterian Hospital, discusses the treatment approach for patients with breast implant-associated anapestic large cell lymphoma (ALCL). According to Gayle, breast implant-associated ALCL is a relatively new entity, which means the treatment modalities of this disease are still evolving. The cornerstone to this is understanding that with early diagnosis, specifically in patients with stage I or II disease where there is no spread beyond the breast, the capsule, and surrounding tissue, the best approach to treatment is total capsulectomy. Total capsulectomy is defined as an unlocked resection, which Gayle explains as removal of the implant, surrounding capsule, and any surrounding mass within the soft tissue. Radiation and chemotherapy are adjunct to total capsulectomy. However, Gayle says these treatment options to not have a primary role in patients diagnosed with relatively early disease. Overall, the treatment of breast implant-associated ALCL is interdisciplinary. Patients are seen by plastic surgeons and surgical oncologists, as well as radiation oncologists and medical oncologists, to determine whether additional treatment is required. For more resources and information regarding lymphoma: https://www.targetedonc.com/clinical/...